Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with Sofosbuvir and Ledipasvir

Zobair M. Younossi, Maria Stepanova, William Balistreri, Kathleen Schwarz, Karen F. Murray, Philip Rosenthal, Sanjay Bansal, Sharon Hunt

Research output: Contribution to journalArticle

Abstract

Objective: The aim of the study was to assess the effect of treatment with ledipasvir/sofosbuvir (LDV/SOF) on the health-related quality of life (HRQL) of pediatric patients with chronic hepatitis C virus (HCV) infection. Methods: Adolescents (12-17 years) with HCV were treated with LDV/SOF (90/400mgdaily) for12weeks.HRQLwasassessedusingthePedsQLv4.0-SF15 completed by the children and caregivers before, during, and after treatment. Results: We included 100 adolescents with HCV genotype 1 infection (14.7±2.0 years, 1% known cirrhosis, 80% treatment-naïve, 97% sustained virologic response-12). At baseline, HRQL the caregiver- perceived HRQL scores were lower than adolescents' self-reported scores (by 6.7-7.9 points, all P<0.01). At the end of 12 weeks of treatment, however, the caregiver-reported HRQL scores showed a significant improvement (+all P<0.04), whereas the adolescents' self-reported scores did not change fromthe baseline.HRQLscores reported by caregivers remained higher than baseline (by+4.7-+7.5, P<0.01) through 12weeks after treatment, as did the adolescents' self-reportedEmotional Functioning scores (+4.3 from baseline, P=0.0009); observed improvements were sustained after 24 weeks of follow-up (all P<0.04).Multivariate analysis showed that, after adjustment for location, age, and sex, having a history of anxiety and panic disorders were consistent predictors of impaired HRQL in adolescents with HCV infection (P<0.05). Conclusions: Treatment of HCV in adolescents with LDV/SOF is associated with some improvement in HRQL. Caregivers' reports of HRQL in adolescents with HCV significantly increased with treatment and were similar to the adolescent self-reported HRQL after sustained virologic response-12.

Original languageEnglish (US)
Pages (from-to)112-116
Number of pages5
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume66
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Hepatitis C
Genotype
Quality of Life
Hepacivirus
Caregivers
Virus Diseases
Therapeutics
sofosbuvir drug combination ledipasvir
Panic Disorder
Chronic Hepatitis C
Anxiety Disorders
Fibrosis
Multivariate Analysis
Pediatrics
Infection

Keywords

  • Interferon
  • Pediatric patients
  • Quality of life
  • Ribavirin
  • School functioning

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology

Cite this

Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with Sofosbuvir and Ledipasvir. / Younossi, Zobair M.; Stepanova, Maria; Balistreri, William; Schwarz, Kathleen; Murray, Karen F.; Rosenthal, Philip; Bansal, Sanjay; Hunt, Sharon.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 66, No. 1, 01.01.2018, p. 112-116.

Research output: Contribution to journalArticle

Younossi, Zobair M. ; Stepanova, Maria ; Balistreri, William ; Schwarz, Kathleen ; Murray, Karen F. ; Rosenthal, Philip ; Bansal, Sanjay ; Hunt, Sharon. / Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with Sofosbuvir and Ledipasvir. In: Journal of Pediatric Gastroenterology and Nutrition. 2018 ; Vol. 66, No. 1. pp. 112-116.
@article{03683f85b97749b486c1810e7570ec5d,
title = "Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with Sofosbuvir and Ledipasvir",
abstract = "Objective: The aim of the study was to assess the effect of treatment with ledipasvir/sofosbuvir (LDV/SOF) on the health-related quality of life (HRQL) of pediatric patients with chronic hepatitis C virus (HCV) infection. Methods: Adolescents (12-17 years) with HCV were treated with LDV/SOF (90/400mgdaily) for12weeks.HRQLwasassessedusingthePedsQLv4.0-SF15 completed by the children and caregivers before, during, and after treatment. Results: We included 100 adolescents with HCV genotype 1 infection (14.7±2.0 years, 1{\%} known cirrhosis, 80{\%} treatment-na{\"i}ve, 97{\%} sustained virologic response-12). At baseline, HRQL the caregiver- perceived HRQL scores were lower than adolescents' self-reported scores (by 6.7-7.9 points, all P<0.01). At the end of 12 weeks of treatment, however, the caregiver-reported HRQL scores showed a significant improvement (+all P<0.04), whereas the adolescents' self-reported scores did not change fromthe baseline.HRQLscores reported by caregivers remained higher than baseline (by+4.7-+7.5, P<0.01) through 12weeks after treatment, as did the adolescents' self-reportedEmotional Functioning scores (+4.3 from baseline, P=0.0009); observed improvements were sustained after 24 weeks of follow-up (all P<0.04).Multivariate analysis showed that, after adjustment for location, age, and sex, having a history of anxiety and panic disorders were consistent predictors of impaired HRQL in adolescents with HCV infection (P<0.05). Conclusions: Treatment of HCV in adolescents with LDV/SOF is associated with some improvement in HRQL. Caregivers' reports of HRQL in adolescents with HCV significantly increased with treatment and were similar to the adolescent self-reported HRQL after sustained virologic response-12.",
keywords = "Interferon, Pediatric patients, Quality of life, Ribavirin, School functioning",
author = "Younossi, {Zobair M.} and Maria Stepanova and William Balistreri and Kathleen Schwarz and Murray, {Karen F.} and Philip Rosenthal and Sanjay Bansal and Sharon Hunt",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/MPG.0000000000001754",
language = "English (US)",
volume = "66",
pages = "112--116",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with Sofosbuvir and Ledipasvir

AU - Younossi, Zobair M.

AU - Stepanova, Maria

AU - Balistreri, William

AU - Schwarz, Kathleen

AU - Murray, Karen F.

AU - Rosenthal, Philip

AU - Bansal, Sanjay

AU - Hunt, Sharon

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: The aim of the study was to assess the effect of treatment with ledipasvir/sofosbuvir (LDV/SOF) on the health-related quality of life (HRQL) of pediatric patients with chronic hepatitis C virus (HCV) infection. Methods: Adolescents (12-17 years) with HCV were treated with LDV/SOF (90/400mgdaily) for12weeks.HRQLwasassessedusingthePedsQLv4.0-SF15 completed by the children and caregivers before, during, and after treatment. Results: We included 100 adolescents with HCV genotype 1 infection (14.7±2.0 years, 1% known cirrhosis, 80% treatment-naïve, 97% sustained virologic response-12). At baseline, HRQL the caregiver- perceived HRQL scores were lower than adolescents' self-reported scores (by 6.7-7.9 points, all P<0.01). At the end of 12 weeks of treatment, however, the caregiver-reported HRQL scores showed a significant improvement (+all P<0.04), whereas the adolescents' self-reported scores did not change fromthe baseline.HRQLscores reported by caregivers remained higher than baseline (by+4.7-+7.5, P<0.01) through 12weeks after treatment, as did the adolescents' self-reportedEmotional Functioning scores (+4.3 from baseline, P=0.0009); observed improvements were sustained after 24 weeks of follow-up (all P<0.04).Multivariate analysis showed that, after adjustment for location, age, and sex, having a history of anxiety and panic disorders were consistent predictors of impaired HRQL in adolescents with HCV infection (P<0.05). Conclusions: Treatment of HCV in adolescents with LDV/SOF is associated with some improvement in HRQL. Caregivers' reports of HRQL in adolescents with HCV significantly increased with treatment and were similar to the adolescent self-reported HRQL after sustained virologic response-12.

AB - Objective: The aim of the study was to assess the effect of treatment with ledipasvir/sofosbuvir (LDV/SOF) on the health-related quality of life (HRQL) of pediatric patients with chronic hepatitis C virus (HCV) infection. Methods: Adolescents (12-17 years) with HCV were treated with LDV/SOF (90/400mgdaily) for12weeks.HRQLwasassessedusingthePedsQLv4.0-SF15 completed by the children and caregivers before, during, and after treatment. Results: We included 100 adolescents with HCV genotype 1 infection (14.7±2.0 years, 1% known cirrhosis, 80% treatment-naïve, 97% sustained virologic response-12). At baseline, HRQL the caregiver- perceived HRQL scores were lower than adolescents' self-reported scores (by 6.7-7.9 points, all P<0.01). At the end of 12 weeks of treatment, however, the caregiver-reported HRQL scores showed a significant improvement (+all P<0.04), whereas the adolescents' self-reported scores did not change fromthe baseline.HRQLscores reported by caregivers remained higher than baseline (by+4.7-+7.5, P<0.01) through 12weeks after treatment, as did the adolescents' self-reportedEmotional Functioning scores (+4.3 from baseline, P=0.0009); observed improvements were sustained after 24 weeks of follow-up (all P<0.04).Multivariate analysis showed that, after adjustment for location, age, and sex, having a history of anxiety and panic disorders were consistent predictors of impaired HRQL in adolescents with HCV infection (P<0.05). Conclusions: Treatment of HCV in adolescents with LDV/SOF is associated with some improvement in HRQL. Caregivers' reports of HRQL in adolescents with HCV significantly increased with treatment and were similar to the adolescent self-reported HRQL after sustained virologic response-12.

KW - Interferon

KW - Pediatric patients

KW - Quality of life

KW - Ribavirin

KW - School functioning

UR - http://www.scopus.com/inward/record.url?scp=85039710637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039710637&partnerID=8YFLogxK

U2 - 10.1097/MPG.0000000000001754

DO - 10.1097/MPG.0000000000001754

M3 - Article

C2 - 28957984

AN - SCOPUS:85039710637

VL - 66

SP - 112

EP - 116

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 1

ER -